A new post-grant review petition has been filed at the Patent Trial and Appeal Board against Straumann USA, LLC, opening what could become a closely watched dispute for practitioners in the dental and medical-device patent space. The proceeding, PGR2026-00070, was filed on August 11, 2026. View full case on Docket Alarm

At this early stage, the PTAB docket identifies Straumann USA, LLC in the case caption, but practitioners will want to watch the filing record closely to confirm the specific patent number at issue, the named petitioner, and the precise claims challenged once the petition and related papers are available through the docket. Because this is a post-grant review rather than an inter partes review, the challenged patent is likely a recently issued patent subject to the broader invalidity framework available under the America Invents Act.

That distinction matters. In PGR, a petitioner may raise not only anticipation and obviousness challenges based on patents and printed publications, but also other invalidity theories, including written description, enablement, indefiniteness, and patent-eligibility issues where applicable. As a result, the grounds for review in this matter may extend well beyond prior art combinations and into claim drafting and specification support—issues that can have consequences across an entire portfolio.

For in-house IP counsel and PTAB litigators, this case is worth following for several reasons. First, Straumann is a major player in the dental implant and related technology markets, so any PTAB challenge involving its patent assets may have broader competitive significance. Second, PGR proceedings often provide a useful window into how petitioners frame full-spectrum validity attacks against newly issued patents, particularly in technically dense life-sciences and medical-device sectors. Third, if the Board institutes review, the institution decision could offer guidance on how the PTAB is approaching threshold sufficiency for non-prior-art challenges in 2026.

Patent prosecutors should also pay attention. Cases like this can highlight drafting vulnerabilities that become central in PGR practice, especially around claim clarity, support for functional limitations, and the adequacy of technical disclosure. For litigators, the matter may also shed light on parallel district court strategy, stays, and the use of PTAB proceedings as leverage in larger commercial disputes.

As the docket develops, key items to monitor will include the petition itself, any preliminary response, the Board’s institution decision, and whether the parties frame the case around prior art alone or broader Section 112 and Section 101 theories. This is the kind of early-stage PTAB matter that can quickly become important once the underlying patent and grounds come into focus.

A new post-grant review at the Patent Trial and Appeal Board could be worth close attention for companies operating in the dental implant and medical device space. In PGR2026-00070, filed on August 11, 2026, the proceeding is captioned Straumann USA, LLC, signaling a challenge to a recently issued patent associated with one of the best-known names in dental technology.

At this stage, the docket entry identifies the matter by party name and PTAB number, but practitioners will want to watch for the petition and related filings to clarify the specific patent claims at issue, the identity of the petitioner, and the precise invalidity theories being advanced. In a post-grant review, however, the stakes are often broader than in inter partes review. PGR allows a challenger to raise a wider set of patentability defenses, including not only prior-art-based attacks under Sections 102 and 103, but also Section 112 issues such as written description, enablement, and indefiniteness, as well as subject-matter eligibility under Section 101 where appropriate.

That broader statutory toolkit is one reason this case may matter to patent prosecutors and in-house IP counsel. If the challenged patent is central to a product line, platform technology, or enforcement strategy, a PGR can become an early and aggressive vehicle for testing claim scope and specification support. For patent owners, these proceedings can expose vulnerabilities in drafting that would not necessarily be reachable in an IPR. For petitioners, they offer a chance to press multiple theories at once during the narrow window after patent issuance.

For life sciences and device companies in particular, any PTAB challenge involving Straumann is notable. The company’s portfolio sits in a commercially important and technically specialized sector, where claim construction, support for functional limitations, and distinctions over dense prior art can be outcome-determinative. If institution is granted, the case could provide useful guidance on how the Board approaches patentability challenges in this industry segment.

Patent practitioners should also monitor the case for procedural developments: whether the Board finds the petition sufficiently particularized, how the patent owner responds on discretionary and merits grounds, and whether expert declarations shape the institution decision. Even before a final written decision, those filings can offer valuable insight into PTAB strategy for newly issued medical-device patents.

View full case on Docket Alarm